Email this article Cardiovascular risk in psoriatic arthritis
- Authors: Badokin VV, Yanysheva AV, Aleksandrova EN, Mach ES, Popkova TV, Badokin VV, Yanysheva AV, Alexandrova EN, Mach ES, Popkova TV
- Issue: Vol 81, No 6 (2009)
- Pages: 41-46
- Section: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/30369
- ID: 30369
Cite item
Full Text
Abstract
Material and methods. The examination covered 61 PA patients (52.9% females) aged 30-55 years and 45 controls without inflammatory and degeneratory diseases matched by gender, age and body mass. Standard cardiovascular risk factors were analysed. C-reactive protein was measured with a highly sensitive method. Carotid arteries were subjected to duplex scanning.
Results. PA patients had a high cardiovascular risk. Dyslipidemia manifested with a high total cholesterol, LDLP cholesterol which correlated with inflammation activity. PA was more frequently associated with subclinical atherosclerosis and atherosclerotic plaques.
Conclusion. Chronic immune inflammation underlying pathogenesis of PA contributes to development of early atherosclerosis and its complications. A high cardiovascular risk is a constituent of PA which had an impact on long-term prognosis of this disease.
Keywords
About the authors
V V Badokin
A V Yanysheva
E N Aleksandrova
E S Mach
T V Popkova
V V Badokin
A V Yanysheva
E N Alexandrova
E S Mach
T V Popkova
References
- Бадокин В. В. Псориатический артрит: клиника, диагностика, лечение: Дис. ... д-ра мед. наук. М. 2003.
- Gladman D. D., Farewell W. T., Wong K., Husted J. Mortality stadies in psoriatic arthritis. Arthr. and Rheum. 1998; 41: 1103-1110.
- Roberts M. E., Wright V., Hill A. G. S., Mehra A. C. Psoriatic arthritis. Ann. Rheum. Dis. 1976; 35 (3): 206-212.
- Wong K., Gladman D. D., Husted J. et al. Mortality stadies in psoriatic arthritis. Arthr. and Rheum. 1997; 40 (10): 1868-1872.
- Ross R. Atherosclerosis - an inflammatory disease. N. Engl. J. Med. 1999; 340: 115-126.
- Albert M. A., Glynn R. J., Ridcer P. M. Plasma concentration of C-reactive protein and the calculated Framingham Coronary Heart Disease score. Circulation 2003; 108: 161-165.
- Насонов Е. Л., Попкова Т. В. Кардиоваскулярные проблемы ревматологии. Науч.-практ. ревматол. 2004; 4: 4-9.
- Wang T. J., Nam B.-H., Wilson P. et al. Association of C-reactive protein with carotid atherosclerosis in men and women: the Framingham Heart Study. Arteroscler. Thromb. Vasc. Biol. 2002; 22: 1662-1667.
- Kumeda Y., Inaba M., Goto H. et al. Increased thickness of the arterial intima-media detected by ultrasonography in patients with rheumatoid arthritis. Arthr. and Rheum. 2002; 46: 1489-1497.
- Попкова Т. В., Алекберова З. С., Александрова Е. Н. и др. Факторы риска кардиоваскулярных нарушений и атеросклероза при системной красной волчанке. Науч.-практ. ревматол. 2004; 4: 10-13.
- Попкова Т. В., Хелковская А. Н., Мач Э. С. и др. Сердечно-сосудистые заболевания при ревматоидном артрите. Науч.-практ. ревматол. 2007; 5: 9-14.
- Sapiro J., Kohen A., David M. et al. Association between psoriasis, diabetes mellitus and artherosclerosis. A case control study. In: 1st World psoriasis and psoriatic arthritis conference 2006: Abstract. Stockholm; 2006; 53: 26.
- Sommer D. M., Jenisch S., Suchan M. et al. Increased prevalence of metabolic syndrome in patients with moderate to severe psoriasis. Arch. Dermatol. Res. 2006; 298 (7): 321-328.
- Tam L. S., Tomlinson B., Chu T. T. et al. Cardiovascular risk profile of patients with psoriatic arthritis compared to controls: the role of inflammation. Rheumatology (Oxford) 2008, 47: 718-723.
- Tam L. S., Shang Q., Li E. K. et al. Subclinical atherosclerosis in patients with psoriatic arthritis. Arthr. and Rheum. 2008; 59: 1322-1331.
- Kimhi O., Caspi D., Borstein N. et al. Prevalence and risk factors of atherosclerosis in patients with psoriatic arthritis. Semin. Arthr. Rheum. 2007; 36: 203-209.
- Gonzalez-Juanatey C., Llorca J., Amigo-Diaz E. et al. High prevalence of subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthr. and Rheum. 2007; 57: 1074-1080.
- Neimann A. L., Shin D. B., Wang X. et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J. Am. Acad. Dermatol. 2006; 55: 829-835.
- Mallbris L., Ritchlin C. T., Stahle M. Metabolic disoders in psoriasis and psoriatic arthritis. Curr. Rheumatol. Rep. 2006; 8 (5): 355-363.
- Skoczynska A. H., Turczyn B., Barancewicz-Lozek M. et al. High density lipoprotein cholesterol in patients with psoriatic arthritis. J. Eur. Acad. Dermatol. Venerol. 2003; 17: 362-363.
- Jones S. M., Harris C. P. D., Lloyd J. et al. Lipoproteins and their subfractions in psoriatic arthritis: identification of an atherogenic profile with active joint disease. Ann. Rheum. Dis. 2000; 59 (5): 904-909.
- Han C., Robinson D. W., Hackett M. V. et al. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J. Rheumatol. 2006, 33: 2167-2172.
- Gisondi P., Tessari G., Conti A. et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br. J. Dermatol. 2007; 157 (1): 68-73.
- Насонов Е. Л. Иммунологические маркеры атеросклероза. Тер. арх. 2002; 5: 80-85.
- Середавкина Н. В., Решетняк Т. М., Буренчев Д. В. и др. Атеросклеротическое поражение коронарных артерий и цереброваскулярные повреждения у больной системной красной волчанкой с антифосфолипидным синдромом. Науч.-практ. ревматол. 2008; 3: 95-101.
- Eder L., Zisman D., Barzilai M. et al. Subclinical artherosclerosis in psoriatic arthritis: a case-control study. J. Rheumatol. 2008, 35: 877-882.
Supplementary files
